Skip to main content
Background gradient from blue to magenta.

Identifying patients for RHAPSIDO® (remibrutinib)

See the characteristics that can help you identify appropriate patients for RHAPSIDO

Which of your patients are ready for the next step in their treatment plan? Every patient’s experience with CSU is different, but there are key characteristics that can help you identify when to start RHAPSIDO.

Meet Emma, Charlotte, and Alex*

Emma doesn't want to sit and wait if there's more that can be done. Patient portrayal.

*Hypothetical patient profiles.

  • Age: 25 years  

  • Has been struggling with CSU symptoms for about 3 months

Symptoms
  • A couple of flares a week with unrelenting itch

  • When symptoms remain after 2 to 4 weeks on increased doses of antihistamines, urticaria treatment guidelines recommend advancing treatment1

Treatment
  • Has had her antihistamine dose increased on several occasions

  • Visited the ER during her most extreme flare; has been given steroids in the past

Burden
  • Reported having to cancel plans due to flares of hives and itch

RHAPSIDO is for your patients like Emma who remain symptomatic despite antihistamines and are proactively searching for more relief from their CSU symptoms.2

Charlotte has tried 3 different antihistamines, but her hives keep coming back. Patient portrayal.

*Hypothetical patient profiles.

  • Age: 32 years  

  • Has been struggling with CSU symptoms for around 6 months

Symptoms
  • 3+ flares a week with intense itch; experiences occasional angioedema

  • RHAPSIDO was studied in a range of patient subgroups with varying disease severities, including patients with a history of angioedema3

Treatment
  • Has tried 3 different antihistamines, up-dosing by 4x each time

Burden
  • Constantly worries about her severe symptoms during unpredictable flares

  • Intense itch has left her scratching through the day and night on multiple occasions

RHAPSIDO is for your patients like Charlotte who struggle with CSU symptoms and want to try something else in addition to antihistamines.2

Alex is open to trying something else—especially if it's not an injection. Patient portrayal.

*Hypothetical patient profiles.

  • Age: 41 years  

  • Has been struggling with CSU symptoms for 9 months

Symptoms
  • Consistently experiences at least 1 to 2 flares of hives and itch a week

  • After 2 to 4 weeks of persistent CSU symptoms on an increased dose of antihistamine treatment, continuing antihistamines alone is not recommended1

Treatment
  • Takes an increased dose of antihistamines every day

  • Despite his prolonged struggle, he prefers to stay on an oral regimen

Burden
  • Flares of hives and itch have caused him to miss or reschedule meetings

RHAPSIDO is for your patients like Alex who remain symptomatic despite antihistamines but want to stay on an oral regimen.2

Many patients take antihistamines but still struggle with CSU4,5

CSU symptoms can last months, years, or sometimes longer. It’s a long-term condition that requires continued management. When patients are unable to control their symptoms, having CSU can feel frustrating.4,6–8 

2-year calendar icon.

average time to diagnosis7

~50% pie chart.

of patients remain symptomatic despite antihistamines4

Even on increased doses of antihistamines, 1 in 2 patients continue to experience symptoms.

Patients with CSU experience a spontaneous occurrence of wheals or angioedema or both due to no known external triggers. You play a crucial role in helping them understand the facts.4,6,9,10

RHAPSIDO targets BTK2

Relief from hives and itch2

BTK, Bruton’s tyrosine kinase; CSU, chronic spontaneous urticaria; MOA, mechanism of action.
References: 1. Zuberbier T, Latiff AHA, Abuzakouk M, et al. The international EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734–766. doi:10.1111/all.15090 2. Rhapsido. Prescribing information. Novartis Pharmaceuticals Corp. 3. Data on file. CSR Study No. CLOU064A2302. Novartis Pharmaceuticals Corp; June 2024. 4. Kaplan A, Lebwohl M, Giménez-Arnau AM, Hide M, Armstrong AW, Maurer M. Chronic spontaneous urticaria: focus on pathophysiology to unlock treatment advances. Allergy. 2023;78(2):389–401. doi:10.1111/all.15603 5. Data on file. CSU Prevalence & Uncontrolled Patients Claims. Novartis Pharmaceuticals Corp; April 2024. 6. Saini SS, Kaplan AP. Chronic spontaneous urticaria: the devil’s itch. J Allergy Clin Immunol Pract. 2018;6(4):1097–1106. doi:10.1016/j.jaip.2018.04.013 7. Maurer M, Abuzakouk M, Bérard F, et al. The burden of chronic spontaneous urticaria is substantial: real-world evidence from ASSURE-CSU. Allergy. 2017;72(12):2005–2016. doi:10.1111/all.13209 8. Goldstein S, Eftekhari S, Mitchell L, et al. Perspectives on living with chronic spontaneous urticaria: from onset through diagnosis and disease management in the US. Acta Derm Venereol. 2019;99(12):1091–1098. doi:10.2340/00015555-3282 9. Sánchez-Borges M, Ansotegui IJ, Baiardini I, et al. The challenges of chronic urticaria part 1: epidemiology, immunopathogenesis, comorbidities, quality of life, and management. World Allergy Organ J. 2021;14(6):100533. doi:10.1016/j.waojou.2021.100533 10. Maurer M, Raap U, Staubach P, et al. Antihistamine-resistant chronic spontaneous urticaria: 1-year data from the AWARE study. Clin Exp Allergy. 2019;49(5):655–662. doi:10.1111/cea.13309